Cytek Biosciences, Inc.
CTKB
$5.36
-$0.03-0.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.67% | 10.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.67% | 10.00% | |||
| Cost of Revenue | 13.83% | 2.04% | |||
| Gross Profit | 15.44% | 18.41% | |||
| SG&A Expenses | 8.27% | 1.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.35% | -0.37% | |||
| Operating Income | 13.48% | 29.06% | |||
| Income Before Tax | -14.67% | 39.86% | |||
| Income Tax Expenses | -92.20% | -976.47% | |||
| Earnings from Continuing Operations | 1.88% | 51.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.88% | 51.03% | |||
| EBIT | 13.48% | 29.06% | |||
| EBITDA | 16.72% | 33.33% | |||
| EPS Basic | 2.50% | 50.45% | |||
| Normalized Basic EPS | -14.07% | 39.16% | |||
| EPS Diluted | 2.50% | 51.11% | |||
| Normalized Diluted EPS | -14.07% | 39.16% | |||
| Average Basic Shares Outstanding | 0.48% | -1.09% | |||
| Average Diluted Shares Outstanding | 0.48% | -1.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||